Exicure’s (OTCQB:XCUR) common stock will begin trading on the Nasdaq Capital Market under the symbol “XCUR” at the opening of trading on July 31, 2019. Exicure also priced its public offering of 27,500,000 shares of its...
By Len Zehr As CEO of closely-held AuraSense Therapeutics, Dr. David Giljohann is one of the original inventors of the company’s technology for first-in-class therapies based on its proprietary spherical nucleic acid...